<--- Back to Details
First PageDocument Content
Ribbon symbolism / Trastuzumab / Bristol-Myers Squibb / HER2/neu / Lapatinib / Paclitaxel / Adjuvant therapy / Breast cancer / Predictive marker / Chemistry / Organic chemistry / Cancer treatments
Date: 2012-10-23 20:37:12
Ribbon symbolism
Trastuzumab
Bristol-Myers Squibb
HER2/neu
Lapatinib
Paclitaxel
Adjuvant therapy
Breast cancer
Predictive marker
Chemistry
Organic chemistry
Cancer treatments

Microsoft PowerPoint - Hayes.ppt

Add to Reading List

Source URL: biospecimens.cancer.gov

Download Document from Source Website

File Size: 788,24 KB

Share Document on Facebook

Similar Documents

Biomarkers / Biotechnology / Chemical pathology / Personalized medicine / Predictive marker / Ras subfamily / Oncotype DX / Medicine / Biology / Genetics

Microsoft Word - 100741workpaper

DocID: 12S1o - View Document

Biomarkers / Biotechnology / Chemical pathology / Personalized medicine / Predictive marker / Ras subfamily / Oncotype DX / Medicine / Biology / Genetics

Microsoft Word - 100741workpaper

DocID: 12OkF - View Document

Chemistry / Oncology / Cancer treatments / Breast cancer / HER2/neu / Targeted therapy / Biologic / Breast cancer chemotherapy / Predictive marker / Medicine / Trastuzumab / Ribbon symbolism

Trastuzumab (Herceptin) Factsheet This factsheet explains what trastuzumab is, how it works, when it may be given, its benefits and the possible side effects.

DocID: 10Wbv - View Document

Oncotype DX / Ribbon symbolism / Breast cancer / Trastuzumab / HER2/neu / Adjuvant therapy / Tamoxifen / Metastatic breast cancer / Predictive marker / Medicine / Cancer treatments / Oncology

1342 Consultation Decision Analytical Protocol (DAP) to guide the assessment of gene expression profiling of 21 genes in breast cancer assay to quantify the risk of disease recurrence and predict adjuvant chemotherapy be

DocID: 10LqM - View Document

Trastuzumab / HER2/neu / Biology / Breast cancer / Management of cancer / Predictive marker / Breast cancer chemotherapy / Ribbon symbolism / Medicine / Cancer treatments

Public Summary Document Application No. 1230 – HER2 ISH testing for access to trastuzumab for neoadjuvant breast cancer Applicant: Roche Products Pty Ltd Australia Date of MSAC consideration: 2 August 2012

DocID: VGAo - View Document